Ferring Pharmaceuticals and Nippon Kayaku said on March 30 that they have entered into a co-promotion agreement in Japan for nadofaragene firadenovec, a gene therapy currently under regulatory review for non-muscle invasive bladder cancer (NMIBC). Under the deal, the two…
To read the full story
Related Article
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
BUSINESS
- Capricor Sues Nippon Shinyaku over US Rights to DMD Cell Therapy
May 11, 2026
- Kyowa Kirin to Consolidate Domestic Research Sites in Yokohama
May 11, 2026
- Kissei Sublicenses Taiwan Rights for Rigel’s AML Drug to OEP
May 11, 2026
- Japan Review Underway for Rhythm’s Acquired Hypothalamic Obesity Drug
May 11, 2026
- FDA Delays Review of Leqembi Iqlik for Alzheimer’s Initiation Therapy
May 11, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





